Danaher Corporation (NYSE:DHR) is one of the best healthcare stocks to buy with highest upside potential. Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a little cheaper on P/E”. It added that the Masimo (MASI) transaction “confused us about DHR’s identity.”
Danaher Corporation also received a rating update from RBC Capital on May 14. The firm resumed coverage of the stock with an Outperform rating, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in the bioprocess market. It further added that factors like the lapping of “idiosyncratic headwinds”, a sustained bioprocess rebound, and end market improvement put the company’s 6% revenue growth target within reach for 2027.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
